

17 February 2020 ASX Code: MXC

Notice Under Section 708A(5)(e) of the Corporations Act

A S X

MGC Pharmaceuticals Limited (ACN 116 800 269) (ASX:MXC) (**Company**), gives this notice pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) and *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547.*

The Company will make offers to issue fully paid ordinary shares (**Shares**) under a share purchase plan without disclosure to investors under Part 6D.2 of the *Corporations Act 2001* (Cth).

The Company hereby confirms that:

- 1. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of the Corporations Act; and
- as at the date of this notice, there is no information to be disclosed which is excluded information (as defined in section 708A(7) of the Corporations Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

--Ends--

Authorised for issue by the Board, for further information, please contact:

UK IR/Media Advisors
Catherine Leftley/Megan Dennison
St Brides Partners Ltd
+44 (0) 207 236 1177
megan@stbridespartners.co.uk

megan@stbridespartners.co.uk catherine@stbridespartners.co.uk MGC Pharmaceuticals Ltd Brett Mitchell Executive Chairman +61 8 6382 3390 info@mgcpharma.com.au